S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.21%)
T   16.80 (+1.27%)
F   12.14 (+0.17%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.44 (+0.45%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.21%)
T   16.80 (+1.27%)
F   12.14 (+0.17%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.44 (+0.45%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.21%)
T   16.80 (+1.27%)
F   12.14 (+0.17%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.44 (+0.45%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.21%)
T   16.80 (+1.27%)
F   12.14 (+0.17%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.44 (+0.45%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
NYSE:ELAN

Elanco Animal Health (ELAN) Stock Price, News & Analysis

$16.37
+0.22 (+1.36%)
(As of 05:16 PM ET)
Today's Range
$16.06
$16.44
50-Day Range
$13.66
$16.41
52-Week Range
$7.88
$16.56
Volume
7.68 million shs
Average Volume
4.87 million shs
Market Capitalization
$8.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.64

Elanco Animal Health MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
4.4% Downside
$15.64 Price Target
Short Interest
Healthy
1.99% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-4.69
Upright™ Environmental Score
News Sentiment
0.39mentions of Elanco Animal Health in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-3.30%
From $0.91 to $0.88 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.80 out of 5 stars

Medical Sector

655th out of 939 stocks

Pharmaceutical Preparations Industry

305th out of 439 stocks


ELAN stock logo

About Elanco Animal Health Stock (NYSE:ELAN)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. The company was founded in 1954 and is headquartered in Greenfield, Indiana.

ELAN Stock Price History

ELAN Stock News Headlines

Elanco to Participate in Upcoming Investor Conferences
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Elanco Animal Health (ELAN) Scheduled to Post Earnings on Monday
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Elanco Animal Health: A Solid Sale Addresses Leverage
Elanco Announces Sale of Aqua Business for $1.3 Billion
Merck Animal Health to Acquire Elanco’s Aqua Business
Merck to Buy Elanco’s Aqua Business for $1.3 Billion
See More Headlines
Receive ELAN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Elanco Animal Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
2/23/2024
Next Earnings (Confirmed)
2/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Fax
N/A
Employees
9,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.64
High Stock Price Target
$20.00
Low Stock Price Target
$12.00
Potential Upside/Downside
-3.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-78,000,000.00
Pretax Margin
-26.48%

Debt

Sales & Book Value

Annual Sales
$4.42 billion
Cash Flow
$2.60 per share
Book Value
$15.37 per share

Miscellaneous

Free Float
461,259,000
Market Cap
$7.99 billion
Optionable
Optionable
Beta
1.29
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives















ELAN Stock Analysis - Frequently Asked Questions

Should I buy or sell Elanco Animal Health stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Elanco Animal Health in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ELAN shares.
View ELAN analyst ratings
or view top-rated stocks.

What is Elanco Animal Health's stock price target for 2024?

7 analysts have issued twelve-month price targets for Elanco Animal Health's shares. Their ELAN share price targets range from $12.00 to $20.00. On average, they expect the company's stock price to reach $15.64 in the next year. This suggests that the stock has a possible downside of 4.4%.
View analysts price targets for ELAN
or view top-rated stocks among Wall Street analysts.

How have ELAN shares performed in 2024?

Elanco Animal Health's stock was trading at $14.90 at the start of the year. Since then, ELAN stock has increased by 9.9% and is now trading at $16.37.
View the best growth stocks for 2024 here
.

Are investors shorting Elanco Animal Health?

Elanco Animal Health saw a increase in short interest in January. As of January 31st, there was short interest totaling 9,790,000 shares, an increase of 43.1% from the January 15th total of 6,840,000 shares. Based on an average daily volume of 5,320,000 shares, the days-to-cover ratio is presently 1.8 days.
View Elanco Animal Health's Short Interest
.

When is Elanco Animal Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our ELAN earnings forecast
.

How can I listen to Elanco Animal Health's earnings call?

Elanco Animal Health will be holding an earnings conference call on Monday, February 26th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Elanco Animal Health's earnings last quarter?

Elanco Animal Health Incorporated (NYSE:ELAN) announced its earnings results on Tuesday, November, 7th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.06. The company had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.04 billion. Elanco Animal Health had a negative net margin of 26.18% and a positive trailing twelve-month return on equity of 6.99%. The business's quarterly revenue was up 3.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.20 earnings per share.

What guidance has Elanco Animal Health issued on next quarter's earnings?

Elanco Animal Health updated its FY23 earnings guidance on Tuesday, January, 9th. The company provided EPS guidance of $0.88-0.94 for the period, compared to the consensus estimate of $0.91. The company issued revenue guidance of $4.36-4.4 billion, compared to the consensus revenue estimate of $4.38 billion.

What is Jeff Simmons' approval rating as Elanco Animal Health's CEO?

169 employees have rated Elanco Animal Health Chief Executive Officer Jeff Simmons on Glassdoor.com. Jeff Simmons has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Elanco Animal Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Elanco Animal Health investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), QUALCOMM (QCOM), Walt Disney (DIS), Johnson & Johnson (JNJ), AT&T (T), Cisco Systems (CSCO), CVS Health (CVS) and Bristol-Myers Squibb (BMY).

When did Elanco Animal Health IPO?

(ELAN) raised $1.4 billion in an initial public offering on Thursday, September 20th 2018. The company issued 62,900,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Barclays, BNP PARIBAS, BofA Merrill Lynch, Citigroup, Credit Suisse, Deutsche Bank Securities, Evercore ISI, Cowen, Academy Securities, Drexel Hamilton, Mischler Financial Group, Ramirez and The Williams Capital Group were co-managers.

Who are Elanco Animal Health's major shareholders?

Elanco Animal Health's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Dodge & Cox (17.04%), Primecap Management Co. CA (10.27%), Vanguard Group Inc. (10.04%), Price T Rowe Associates Inc. MD (4.32%), Dimensional Fund Advisors LP (3.06%) and Nuveen Asset Management LLC (1.24%). Insiders that own company stock include Art A Garcia, Elanco Animal Health Inc, Jeffrey N Simmons, John P Bilbrey, Michael J Harrington, R David Hoover and Rajeev A Modi.
View institutional ownership trends
.

How do I buy shares of Elanco Animal Health?

Shares of ELAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ELAN) was last updated on 2/23/2024 by MarketBeat.com Staff